Brind.
  1. IDEXX Laboratories' CEO, Mike Erickson, commented on the company's scaling strategy and announced the rollout of new diagnostic services.
  2. IDEXX customers are shifting pancreatic lipase testing to the Catalyst instrument platform.
  3. Higher revenue drove increased profit margin for IDEXX Laboratories, Inc. on August 5, 2025.

FMT and HST contributed $310.9 million and $365.3 million, respectively, to Idex's net sales on July 30, 2025.

1 report, 1 independent Updated Jul 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

FMT and HST contributed $310.9 million and $365.3 million, respectively, to Idex's net sales on July 30, 2025.

Who's involved

What this event is mainly about
FMT

How it developed

Newest first. Tap a step to see who reported it.
  1. Growth in the Health & Science Technologies segment drove Q2 results for IDEX, which provides high-purity gas filtration products.Sub-event
  2. FMT and HST reported specific contributions to Idex's net sales in July 2025.1 source

Keep exploring

Part of

Higher revenue drove increased profit margin for IDEXX Laboratories, Inc. on August 5, 2025. All 1 developments

Within IDEXX Laboratories' CEO, Mike Erickson, commented on the company's scaling strategy and announced the rollout of new diagnostic services.

The entities involved

  • FMT

    company in the Czech Republic

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • ZacksIdex (IEX) Reports Q2 Earnings: What Key Metrics Have to Say For the quarter ended June 2025, Idex (IEX) reported revenue of $865.4 million, up 7.2% over the same period last year. EPS came in at $2.